LINCOLN.NS Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 apr 2024 @ 12:00):

Stats
Dagens volum	23 175.00
Gjennomsnittsvolum	101 918
Markedsverdi	11.90B
EPS	INR0 ( 2024-02-08 )
Neste inntjeningsdato	( INR0 ) 2024-05-22
Last Dividend	INR1.500 ( 2023-09-15 )
Next Dividend	INR0 ( N/A )
P/E	13.63
ATR14	INR0.822 (0.14%)

Volum Korrelasjon

Lang: 0.00 (neutral)

Kort: -0.51 (weak negative)

Signal:(35.258) Neutral

Lincoln Pharmaceuticals Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Lincoln Pharmaceuticals Korrelasjon - Valuta/Råvare

-0.46
( neutral )

-0.48
( neutral )

-0.15
( neutral )

-0.39
( neutral )

0.17
( neutral )

0.40
( neutral )

Lincoln Pharmaceuticals Økonomi

Annual	2022
Omsetning:	INR5.10B
Bruttogevinst:	INR2.69B (52.70 %)
EPS:	INR36.40

FY	2022
Omsetning:	INR5.10B
Bruttogevinst:	INR2.69B (52.70 %)
EPS:	INR36.40

FY	2022
Omsetning:	INR4.68B
Bruttogevinst:	INR2.48B (53.06 %)
EPS:	INR34.63

FY	2021
Omsetning:	INR4.15B
Bruttogevinst:	INR2.16B (52.05 %)
EPS:	INR31.11

Financial Reports:

No articles found.

Lincoln Pharmaceuticals Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
INR1.500 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR1.500 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)

Lincoln Pharmaceuticals Dividend Information - Dividend Junior

Dividend Sustainability Score: 4.60 - low (52.89%) | Divividend Growth Potential Score: 5.27 - Stable (5.42%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	INR1.000	2016-09-23
Last Dividend	INR1.500	2023-09-15
Next Dividend	INR0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	8	--
Total Paid Out	INR11.20	--
Avg. Dividend % Per Year	0.32%	--
Score	2.19	--
Div. Sustainability Score	4.60
Div.Growth Potential Score	5.27
Div. Directional Score	4.94	--

Next Divdend (Est)
(2024-06-25)

INR1.526 Estimate 3.10 %

Dividend Stability

0.25 Very Poor

Dividend Score

2.19

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield
2016	INR0	0.00%
2017	INR0	0.00%
2018	INR1.500	0.67%
2019	INR1.500	0.66%
2020	INR1.500	0.73%
2021	INR1.500	0.62%
2022	INR1.500	0.41%
2023	INR1.500	0.42%
2024	INR0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
SUTLEJTEX.NS	Dividend Junior	2023-08-18	Annually	18	1.03%
NDRAUTO.NS	Dividend Junior	2023-07-12	Annually	4	0.59%
ICICIGI.NS	Dividend Junior	2023-06-12	Annually	8	0.36%
CENTENKA.NS	Dividend Junior	2023-08-11	Annually	22	1.85%
RUBYMILLS.NS	Dividend Junior	2023-09-20	Annually	23	0.96%
LINCOLN.NS	Dividend Junior	2023-09-15	Annually	9	0.32%
GEECEE.NS	Dividend Junior	2023-09-08	Sporadic	18	0.97%
ARIHANTCAP.NS	Dividend Junior	2023-07-28	Annually	4	0.39%
TEXINFRA.NS	Dividend Junior	2023-09-18	Annually	20	0.18%
OPTIEMUS.NS	Dividend Junior	2023-06-07	Insufficient data to determine frequency	2	0.16%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.159	1.500	6.83	10.00	[0 - 0.5]
returnOnAssetsTTM	0	1.200	0	0	[0 - 0.3]
returnOnEquityTTM	0.166	1.500	9.26	10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	0	0.800	-5.00	-4.00	[1 - 3]
quickRatioTTM	0	0.800	-4.71	-3.76	[0.8 - 2.5]
cashRatioTTM	0	1.500	-1.111	-1.667	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	47.50	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	10.34	2.00	6.55	10.00	[0 - 30]
freeCashFlowPerShareTTM	10.34	2.00	4.83	9.66	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.487	1.000	5.22	5.22	[0.2 - 0.8]
operatingProfitMarginTTM	0.182	1.000	8.35	8.35	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				4.60

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	13.66	1.000	8.72	0	[1 - 100]
returnOnEquityTTM	0.166	2.50	9.53	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	10.34	2.00	6.55	9.66	[0 - 30]
dividendYielPercentageTTM	0.252	1.500	3.70	0	[0 - 0.4]
operatingCashFlowPerShareTTM	10.34	2.00	6.55	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	2.67	1.500	10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0376	1.000	-1.560	0	[0.1 - 0.5]
Total Score				5.27

Lincoln Pharmaceuticals

Lincoln Pharmaceuticals Limited engages in manufacturing and trading of pharmaceutical products in India and internationally. The company's product portfolio includes dermatologist preparations, gynecological products, gastrointestinal ranges, otology products, and phosphodiesterase type 5 inhibitor and general anesthetics. It provides products in the areas of cough and cold, anti-allergic, and anti-asthmatics; sterile ophthalmic eye drops and ointment; anti-malarial; vitamins, minerals, and antioxidants; anti-bacterial, anti-viral, and anti-fungal vitamins; analgesic and anti-pyretic; anti-psychotic, anti-convulsant, anti-depressant, and anti-diabetic; cardiac anti-hypertensives, and diuretic; and anti-diarrheal, anti-spasmodic, and laxative. The company also offers branded generics. Lincoln Pharmaceuticals Limited was founded in 1979 and is based in Ahmedabad, India.